Multi-Specific Biologics Take Aim at the Eczema Efficacy Gap
A Frontiers review maps 18 bispecific and trispecific antibodies for atopic dermatitis after registry data showed ~85% of biologic-treated patients miss EASI 90 or itch NRS 0/1 at 12 months.